Understanding Cannabis Use Disorder — how dependence develops, who is most at risk, how it’s diagnosed, and the evidence-based treatment that supports recovery at Thamarai, Pollachi.
Cannabis Use Disorder (CUD) is a clinically recognised pattern of cannabis use characterised by an inability to control consumption despite significant impairment or distress. It sits within the broader category of substance use disorder, and — contrary to a common assumption that cannabis is “non-addictive” — is a well-documented condition with its own dependence syndrome, withdrawal profile, and diagnostic criteria under DSM-5 and ICD-11.
Rates of Cannabis Use Disorder have risen alongside increasing potency of cannabis products and evolving legal and social attitudes toward use in many parts of the world. While a large proportion of people who use cannabis do not develop dependence, a meaningful minority do — and risk rises sharply with earlier age of first use, frequency of use, and higher-potency products.
Cannabis dependence is often underestimated because withdrawal is less physically dramatic than with alcohol or opioids. But the impact on motivation, cognition, mental health and daily functioning can be just as significant — and just as treatable.
Not sure if what you’re experiencing is Cannabis Use Disorder or just heavy use? A confidential conversation with our clinical team can help clarify.
Cannabis dependence develops gradually, often masked by cannabis’s reputation as a “low-risk” substance. Withdrawal, while rarely medically dangerous, can be significant enough to drive continued use.
Several factors increase the likelihood that cannabis use will progress to a diagnosable use disorder.
Starting cannabis use during adolescence, while the brain is still developing, significantly raises the likelihood of later dependence.
Higher-THC cannabis products, increasingly common in today’s market, are associated with faster onset of dependence and greater psychological risk.
Anxiety, depression, and trauma are strongly linked to cannabis use as a coping mechanism, which can accelerate dependence.
Daily or near-daily use carries substantially higher risk of developing dependence than occasional or social use.
A family history of substance use disorder increases individual vulnerability to cannabis dependence.
Peer use, easy availability, and social or cultural normalisation of cannabis all increase exposure and risk.
Certain groups face distinct, well-documented risks from cannabis use, warranting particular clinical attention.
The adolescent brain continues developing into the mid-twenties, making it especially vulnerable to cannabis’s effects on cognition and mental health.
Cannabis use during pregnancy carries specific risks to fetal development that warrant careful, non-judgemental clinical guidance.
If you’re pregnant, or supporting a young person, our team can guide you through what safe, confidential support looks like for your specific situation.
Diagnosis combines structured clinical criteria with validated, cannabis-specific screening tools to assess severity and guide treatment planning.
Under DSM-5, Cannabis Use Disorder is diagnosed against 11 criteria spanning impaired control, social impairment, risky use, and physiological signs such as tolerance and withdrawal. Severity is graded by the number of criteria present over a 12-month period.
2–3 criteria present. Often responsive to brief intervention and outpatient therapy.
4–5 criteria present. Typically benefits from structured, more intensive therapy.
6 or more criteria present. Often indicates need for structured or residential treatment.
Provides the core diagnostic criteria and severity grading used to formally diagnose Cannabis Use Disorder.
The Cannabis Abuse Screening Test is a brief six-item questionnaire widely used to flag problematic cannabis use, particularly in younger populations.
The Cannabis Use Disorders Identification Test screens for hazardous use, dependence symptoms, and cannabis-related harm.
The Cannabis Use Problems Identification Test assesses the broader impact of cannabis use across physical, psychological and social domains.
The Timeline Followback method maps day-by-day cannabis use over a defined period, helping establish an accurate picture of frequency and quantity.
Screening tools are combined with a full clinical interview and screening for co-occurring mental health or substance use conditions.
Treatment for Cannabis Use Disorder is led by structured psychotherapy and behavioural approaches, with medication used selectively to support recovery.
Cognitive Behavioural Therapy is a first-line treatment, helping individuals identify triggers, manage cravings, and restructure the thought patterns that sustain regular use.
Motivational Enhancement Therapy uses a collaborative, non-confrontational approach to strengthen an individual’s own motivation to change, often used effectively alongside CBT.
A structured, evidence-based approach that provides tangible incentives for verified abstinence, shown to be particularly effective in supporting early recovery from cannabis use.
Structured 12-step based support groups provide peer accountability and a long-term recovery community, complementing individual therapy.
There is currently no medication specifically approved to treat Cannabis Use Disorder. Medication may be used selectively to manage specific withdrawal symptoms, such as sleep disturbance or anxiety, or to treat co-occurring mental health conditions.
All medication decisions are made by our physicians following individual clinical assessment — this page does not recommend specific medications or dosing.
Ready to talk through treatment options for yourself or someone you care about?
Why Families Choose Us
The Thamarai Difference
Treatment is matched to severity, age, and any co-occurring condition, not a fixed template.
Co-occurring anxiety, depression or trauma is assessed and treated alongside cannabis use.
Every enquiry and admission is handled with full discretion, including for adolescent and family cases.
Particularly for younger patients, families are guided and involved appropriately throughout care.
A calm, residential environment in Pollachi designed to support focus away from everyday triggers.
Ongoing relapse-prevention support to protect progress well beyond residential treatment.
Yes. Cannabis Use Disorder is a recognised clinical condition under DSM-5 and ICD-11, with its own dependence and withdrawal profile, even though cannabis is often perceived as low-risk.
Withdrawal symptoms typically begin within a day or two of stopping, peak within the first week, and can persist for two to three weeks, though this varies by individual and frequency of prior use.
Yes, current evidence links cannabis use during pregnancy to potential effects on fetal development and birth weight. Our clinical team offers confidential, non-judgemental guidance for pregnant individuals seeking support.
Our clinical team may use validated tools such as CAST, CUDIT, or CUPIT, alongside a Timeline Followback assessment and DSM-5 criteria, to build an accurate picture of use and severity.
There’s no medication specifically approved for Cannabis Use Disorder. Medication may be used selectively for specific withdrawal symptoms or co-occurring conditions, alongside psychotherapy as the primary treatment.
Speak with our clinical team, in confidence
Whether you’re seeking help for yourself, a young person, or a loved one, our admissions team is here to listen and guide you toward the right level of care.